Glut-1 as a therapeutic target: Increased chemoresistance and HIF-1-independent link with cell turnover is revealed through COMPARE analysis and metabolomic studies

Cancer Chemotherapy and Pharmacology

Volumn 61, Issue 3, 2008, Pages 377-393

  Evans, Andrew ^a   Bates, Victoria ^a   Troy, Helen ^b   Hewitt, Stephen ^c   Holbeck, Susan ^c   Chung, Yuen Li ^b   Phillips, Roger ^d   Stubbs, Marion ^b   Griffiths, John ^b   Airley, Rachel ^a,e  

^a LIVERPOOL JOHN MOORES UNIVERSITY   (United Kingdom)

^b ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

^c NATIONAL CANCER INSTITUTE   (United States)

^d UNIVERSITY OF BRADFORD   (United Kingdom)

^e ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

Author keywords

COMPARE analysis; Glut 1; HIF 1; Metabolomics; NCI60

Indexed keywords

APAZIQUONE; BACTERIAL TOXIN; DACARBAZINE; EPIDERMAL GROWTH FACTOR RECEPTOR; FORMALDEHYDE; GLUCOSE; GLUCOSE TRANSPORTER 1; HYDROGEN; HYPOXIA INDUCIBLE FACTOR 1; LEAD; MEMBRANE LIPID; PARAFFIN; PHOSPHORUS 31; VINCRISTINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLADDER; CELL LINE; CELL LYSATE; CONTROLLED STUDY; CORRELATION ANALYSIS; FIBROSARCOMA; GLYCOLYSIS; HEPATOMA CELL; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; LIPID DEGRADATION; METABOLOMICS; MOUSE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PHOSPHOLIPID METABOLISM; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR CELL; VECTOR CONTROL; WILD TYPE; XENOGRAFT;

ANIMALS; CELL LINE, TUMOR; DATABASES, GENETIC; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG RESISTANCE, NEOPLASM; DRUG SCREENING ASSAYS, ANTITUMOR; FLUORESCENT ANTIBODY TECHNIQUE; GLUCOSE TRANSPORTER TYPE 1; GREEN FLUORESCENT PROTEINS; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; IMMUNOHISTOCHEMISTRY; LIVER NEOPLASMS, EXPERIMENTAL; MAGNETIC RESONANCE SPECTROSCOPY; METABOLISM; PARAFFIN EMBEDDING; TETRAZOLIUM SALTS; THIAZOLES; TISSUE FIXATION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 37249067628     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00280-007-0480-1     Document Type: Article

References (55)

1. Airley R, Loncaster J, Davidson S, Bromley M, Roberts S, Patterson A, Hunter R, Stratford I, West C (2001) Glucose transporter glut-1 expression correlates with tumor hypoxia and predicts metastasis-free survival in advanced carcinoma of the cervix. Clin Cancer Res 7:928-934
2. Airley RE, Loncaster J, Raleigh JA, Harris AL, Davidson SE, Hunter RD, West CM, Stratford IJ (2003) GLUT-1 and CAIX as intrinsic markers of hypoxia in carcinoma of the cervix: relationship to pimonidazole binding. Int J Cancer 104:85-91
3. Airley RE, Phillips RM, Evans AE, Double J, Burger AM, Feibig HH, West CM, Stratford IJ (2005) Hypoxia-regulated glucose transporter Glut-1 may influence chemosensitivity to some alkylating agents: results of EORTC (First Translational Award) study of the relevance of tumour hypoxia to the outcome of chemotherapy in human tumour-derived xenografts. Int J Oncol 26:1477-1484
4. Baron-Delage S, Mahraoui L, Cadoret A, Veissiere D, Taillemite JL, Chastre E, Gespach C, Zweibaum A, Capeau J, Brot-Laroche E, Cherqui G (1996) Deregulation of hexose transporter expression in Caco-2 cells by ras and polyoma middle T oncogenes. Am J Physiol 270: G314-G323
5. Behrooz A, Ismail-Beigi F (1999) Stimulation of glucose transport by hypoxia: signals and mechanisms. News Physiol Sci 14:105-110
6. Bos R, van Diest PJ, de Jong JS, van der Groep P, van der Valk P, van der Wall E (2005) Hypoxia-inducible factor-1alpha is associated with angiogenesis, and expression of bFGF, PDGF-BB, and EGFR in invasive breast cancer. Histopathology 46:31-36
7. Briasoulis E, Judson I, Pavlidis N, Beale P, Wanders J, Groot Y, Veerman G, Schuessler M, Niebch G, Siamopoulos K, Tzamakou E, Rammou D, Wolf L, Walker R, Hanauske A (2000) Phase I trial of 6-hour infusion of glufosfamide, a new alkylating agent with potentially enhanced selectivity for tumors that overexpress transmembrane glucose transporters: a study of the European Organization for Research and Treatment of Cancer Early Clinical Studies Group. J Clin Oncol 18:3535-3544
8. Brizel DM, Sibley GS, Prosnitz LR, Scher RL, Dewhirst MW (1997) Tumor hypoxia adversely affects the prognosis of carcinoma of the head and neck. Int J Radiat Oncol Biol Phys 38:285-289
9. Brown JM (2002) Tumor microenvironment and the response to anticancer therapy. Cancer Biol Ther 1:453-458
10. Brown LM, Cowen RL, Debray C, Eustace A, Erler JT, Sheppard FC, Parker CA, Stratford IJ, Williams KJ (2006) Reversing hypoxic cell chemoresistance in vitro using genetic and small molecule approaches targeting hypoxia inducible factor-1. Mol Pharmacol 69:411-418
11. Cantuaria G, Magalhaes A, Angioli R, Mendez L, Mirhashemi R, Wang J, Wang P, Penalver M, Averette H, Braunschweiger P (2000) Antitumor activity of a novel glyco-nitric oxide conjugate in ovarian carcinoma. Cancer 88:381-388
12. Chan JY, Kong SK, Choy YM, Lee CY, Fung KP (1999) Inhibition of glucose transporter gene expression by antisense nucleic acids in HL-60 leukemia cells. Life Sci 65:63-70
13. Chen J, Zhao S, Nakada K, Kuge Y, Tamaki N, Okada F, Wang J, Shindo M, Higashino F, Takeda K, Asaka M, Katoh H, Sugiyama T, Hosokawa M, Kobayashi M (2003) Dominant-negative hypoxia-inducible factor-1 alpha reduces tumorigenicity of pancreatic cancer cells through the suppression of glucose metabolism. Am J Pathol 162:1283-1291
14. Chi KN, Chia SK, Dixon R, Newman MJ, Wacher VJ, Sikic B, Gelmon KA (2005) A phase I pharmacokinetic study of the P-glycoprotein inhibitor, ONT-093, in combination with paclitaxel in patients with advanced cancer. Invest New Drugs 23:311-315
15. Cooper R, Sarioglu S, Sokmen S, Fuzun M, Kupelioglu A, Valentine H, Gorken IB, Airley R, West C (2003) Glucose transporter-1 (GLUT-1): a potential marker of prognosis in rectal carcinoma?. Br J Cancer 89:870-876
16. Deem RL, Niederlehner A, Targan SR (1986) Active target cell processes, possibly involving receptor-mediated endocytosis, are critical for expression of cytotoxicity by natural killer cell-derived cytolytic factor. Cell Immunol 102:187-197
17. Eubank WB, Mankoff DA (2005) Evolving role of positron emission tomography in breast cancer imaging. Semin Nucl Med 35:84-99
18. Fitzsimmons SA, Workman P, Grever M, Paull K, Camalier R, Lewis AD (1996) Reductase enzyme expression across the National Cancer Institute Tumor cell line panel: correlation with sensitivity to mitomycin C and EO9. J Natl Cancer Inst 88:259-269
19. Gandara DR, Lara PN Jr, Goldberg Z, Le QT, Mack PC, Lau DH, Gumerlock PH (2002) Tirapazamine: prototype for a novel class of therapeutic agents targeting tumor hypoxia. Semin Oncol 29:102-109
20. Grabmaier K, MC AdW, Verhaegh GW, Schalken JA, Oosterwijk E (2004) Strict regulation of CAIX(G250/MN) by HIF-1alpha in clear cell renal cell carcinoma. Oncogene 23:5624-5631
21. Griffiths JR, McSheehy PM, Robinson SP, Troy H, Chung YL, Leek RD, Williams KJ, Stratford IJ, Harris AL, Stubbs M (2002) Metabolic changes detected by in vivo magnetic resonance studies of HEPA-1 wild-type tumors and tumors deficient in hypoxia-inducible factor-1beta (HIF-1beta): evidence of an anabolic role for the HIF-1 pathway. Cancer Res 62:688-695
22. Harris AL (2002) Hypoxia-a key regulatory factor in tumour growth. Nat Rev Cancer 2:38-47
23. Hendriks HR, Pizao PE, Berger DP, Kooistra KL, Bibby MC, Boven E, Dreef-van der Meulen HC, Henrar RE, Fiebig HH, Double JA et al (1993) EO9: a novel bioreductive alkylating indoloquinone with preferential solid tumour activity and lack of bone marrow toxicity in preclinical models. Eur J Cancer 29A:897-906
24. Hopfl G, Wenger RH, Ziegler U, Stallmach T, Gardelle O, Achermann R, Wergin M, Kaser-Hotz B, Saunders HM, Williams KJ, Stratford IJ, Gassmann M, Desbaillets I (2002) Rescue of hypoxia-inducible factor-1alpha-deficient tumor growth by wild-type cells is independent of vascular endothelial growth factor. Cancer Res 62:2962-2970
25. Ishida K, Yamashita H, Katagiri H, Oka Y (1995) Regulation of glucose transporter 1 (GLUT1) gene expression by epidermal growth factor in bovine corneal endothelial cells. Jpn J Ophthalmol 39:225-232
26. Jensen RL, Ragel BT, Whang K, Gillespie D (2006) Inhibition of hypoxia inducible factor-1alpha (HIF-1alpha) decreases vascular endothelial growth factor (VEGF) secretion and tumor growth in malignant gliomas. J Neurooncol 78:233-247
27. Klepper J, Scheffer H, Leiendecker B, Gertsen E, Binder S, Leferink M, Hertzberg C, Nake A, Voit T, Willemsen MA (2005) Seizure control and acceptance of the ketogenic diet in GLUT1 deficiency syndrome: a 2- to 5-year follow-up of 15 children enrolled prospectively. Neuropediatrics 36:302-308
28. Klepper J, Voit T (2002) Facilitated glucose transporter protein type 1 (GLUT1) deficiency syndrome: impaired glucose transport into brain- a review. Eur J Pediatr 161:295-304
29. Levine KB, Cloherty EK, Hamill S, Carruthers A (2002) Molecular determinants of sugar transport regulation by ATP. Biochemistry 41:12629-12638
30. Liu Q, Vera JC, Peng H, Golde DW (2001) The predicted ATP-binding domains in the hexose transporter GLUT1 critically affect transporter activity. Biochemistry 40:7874-7881
31. Malhotra R, Tyson DG, Sone H, Aoki K, Kumagai AK, Brosius FC 3rd (2002) Glucose uptake and adenoviral mediated GLUT1 infection decrease hypoxia-induced HIF-1alpha levels in cardiac myocytes. J Mol Cell Cardiol 34:1063-1073
32. Merrall NW, Plevin R, Gould GW (1993) Growth factors, mitogens, oncogenes and the regulation of glucose transport. Cell Signal 5:667-675
33. Moadel RM, Nguyen AV, Lin EY, Lu P, Mani J, Blaufox MD, Pollard JW, Dadachova E (2003) Positron emission tomography agent 2-deoxy-2-[18F]fluoro-D- glucose has a therapeutic potential in breast cancer. Breast Cancer Res 5:R199-R205
34. Mosmann T (1983) Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods 65:55-63
35. Noguchi Y, Saito A, Miyagi Y, Yamanaka S, Marat D, Doi C, Yoshikawa T, Tsuburaya A, Ito T, Satoh S (2000) Suppression of facilitative glucose transporter 1 mRNA can suppress tumor growth. Cancer Lett 154:175-182
36. Nordsmark M, Bentzen SM, Rudat V, Brizel D, Lartigau E, Stadler P, Becker A, Adam M, Molls M, Dunst J, Terris DJ, Overgaard J (2005) Prognostic value of tumor oxygenation in 397 head and neck tumors after primary radiation therapy. An international multi-center study. Radiother Oncol 77:18-24
37. Oliver RJ, Woodwards RT, Sloan P, Thakker NS, Stratford IJ, Airley RE (2004) Prognostic value of facilitative glucose transporter Glut-1 in oral squamous cell carcinomas treated by surgical resection; results of EORTC Translational Research Fund studies. Eur J Cancer 40:503-507
38. Osthus RC, Shim H, Kim S, Li Q, Reddy R, Mukherjee M, Xu Y, Wonsey D, Lee LA, Dang CV (2000) Deregulation of glucose transporter 1 and glycolytic gene expression by c-Myc. J Biol Chem 275:21797-21800
39. Phillips RM (1998) Prospects for bioreductive drug development. Expert Opin Investig Drugs 7:905-928
40. Phillips RM, Jaffar M, Maitland DJ, Loadman PM, Shnyder SD, Steans G, Cooper PA, Race A, Patterson AV, Stratford IJ (2004) Pharmacological and biological evaluation of a series of substituted 1,4-naphthoquinone bioreductive drugs. Biochem Pharmacol 68:2107-2116
41. Plumb JA, Gerritsen M, Milroy R, Thomson P, Workman P (1994) Relative importance of DT-diaphorase and hypoxia in the bioactivation of EO9 by human lung tumor cell lines. Int J Radiat Oncol Biol Phys 29:295-299
42. Robertson N, Haigh A, Adams GE, Stratford IJ (1994) Factors affecting sensitivity to EO9 in rodent and human tumour cells in vitro: DT-diaphorase activity and hypoxia. Eur J Cancer 30A:1013-1019
43. Ryan HE, Poloni M, McNulty W, Elson D, Gassmann M, Arbeit JM, Johnson RS (2000) Hypoxia-inducible factor-1alpha is a positive factor in solid tumor growth. Cancer Res 60:4010-4015
44. Salas-Burgos A, Iserovich P, Zuniga F, Vera JC, Fischbarg J (2004) Predicting the three-dimensional structure of the human facilitative glucose transporter glut1 by a novel evolutionary homology strategy: insights on the molecular mechanism of substrate migration, and binding sites for glucose and inhibitory molecules. Biophys J 87:2990-2999
45. Sampson JH, Akabani G, Archer GE, Bigner DD, Berger MS, Friedman AH, Friedman HS, Herndon JE 2nd, Kunwar S, Marcus S, McLendon RE, Paolino A, Penne K, Provenzale J, Quinn J, Reardon DA, Rich J, Stenzel T, Tourt-Uhlig S, Wikstrand C, Wong T, Williams R, Yuan F, Zalutsky MR, Pastan I (2003) Progress report of a Phase I study of the intracerebral microinfusion of a recombinant chimeric protein composed of transforming growth factor (TGF)-alpha and a mutated form of the Pseudomonas exotoxin termed PE-38 (TP-38) for the treatment of malignant brain tumors. J Neurooncol 65:27-35
46. Schwartz DL, Rajendran J, Yueh B, Coltrera MD, Leblanc M, Eary J, Krohn K (2004) FDG-PET prediction of head and neck squamous cell cancer outcomes. Arch Otolaryngol Head Neck Surg 130:1361-1367
47. Seidner G, Alvarez MG, Yeh JI, O'Driscoll KR, Klepper J, Stump TS, Wang D, Spinner NB, Birnbaum MJ, De Vivo DC (1998) GLUT-1 deficiency syndrome caused by haploinsufficiency of the blood-brain barrier hexose carrier. Nat Genet 18:188-1891
48. Stubbs M, Van den Boogaart A, Bashford CL, Miranda PM, Rodrigues LM, Howe FA, Griffiths JR (1996) 31P-magnetic resonance spectroscopy studies of nucleated and non-nucleated erythrocytes; time domain data analysis (VARPRO) incorporating prior knowledge can give information on the binding of ADP. Biochim Biophys Acta 1291:143-148
49. Tannock IF, Guttman P, Rauth AM (1983) Failure of 2-deoxy-D-glucose and 5-thio-D-glucose to kill hypoxic cells of two murine tumors. Cancer Res 43:980-983
50. Ullah MS, Davies AJ, Halestrap AP (2006) The plasma membrane lactate transporter MCT4, but not MCT1, is up-regulated by hypoxia through a HIF-1alpha-dependent mechanism. J Biol Chem 281:9030-9037
51. van der Heijden AG, Moonen PM, Cornel EB, Vergunst H, de Reijke TM, van Boven E, Barten EJ, Puri R, van Kalken CK, Witjes JA (2006) Phase II marker lesion study with intravesical instillation of apaziquone for superficial bladder cancer: toxicity and marker response. J Urol 176:1349-53; discussion 1353
52. Vera JC, Reyes AM, Velasquez FV, Rivas CI, Zhang RH, Strobel P, Slebe JC, Nunez-Alarcon J, Golde DW (2001) Direct inhibition of the hexose transporter GLUT1 by tyrosine kinase inhibitors. Biochemistry 40:777-790
53. Williams KJ, Telfer BA, Airley RE, Peters HP, Sheridan MR, van der Kogel AJ, Harris AL, Stratford IJ (2002) A protective role for HIF-1 in response to redox manipulation and glucose deprivation: implications for tumorigenesis. Oncogene 21:282-290
54. Zhang JZ, Behrooz A, Ismail-Beigi F (1999) Regulation of glucose transport by hypoxia. Am J Kidney Dis 34:189-202
55. Zu XL, Guppy M (2004) Cancer metabolism: facts, fantasy, and fiction. Biochem Biophys Res Commun 313:459-465